Cargando…

Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients – a pilot study

BACKGROUND: Mycophenolic acid (MPA) is widely used as part of immunosuppressive regimens following allograft transplantation. The large pharmacokinetic (PK) and pharmacodynamic (PD) variability and narrow therapeutic range of MPA provide a potential for therapeutic drug monitoring. The objective of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bremer, Sara, Vethe, Nils T, Rootwelt, Helge, Jørgensen, Pål F, Stenstrøm, Jean, Holdaas, Hallvard, Midtvedt, Karsten, Bergan, Stein
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724496/ https://www.ncbi.nlm.nih.gov/pubmed/19635156 http://dx.doi.org/10.1186/1479-5876-7-64

Ejemplares similares

Pharmacodynamic assessment of mycophenolic acid in resting and activated target cell population during the first year after renal transplantation
por: Klaasen, Rolf Anton, et al.
Publicado: (2020)

Exposure to Mycophenolate and Fatherhood
por: Midtvedt, Karsten, et al.
Publicado: (2017)

Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Belatacept in Adult Kidney Transplant Recipients
por: Shen, Jinshan, et al.
Publicado: (2013)

Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipient—No Intervention Actually Needed
por: Åsberg, Anders, et al.
Publicado: (2020)

Phase I study of single‐dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients
por: Moudgil, Asha, et al.
Publicado: (2019)

Tacrolimus Measured in Capillary Volumetric Microsamples in Pediatric Patients—A Cross-Validation Study
por: Kindem, Ingvild Andrea, et al.
Publicado: (2021)

The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients
por: Lunde, Ingrid, et al.
Publicado: (2014)

Fasting Status and Circadian Variation Must be Considered When Performing AUC‐based Therapeutic Drug Monitoring of Tacrolimus in Renal Transplant Recipients
por: Gustavsen, Marte Theie, et al.
Publicado: (2020)

Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients
por: Loftheim, Håvard, et al.
Publicado: (2012)

Use of Statins in Kidney Transplant Recipients in Norway
por: Rønning, Marit, et al.
Publicado: (2022)

One-year protocol biopsies from ABO-incompatible renal allografts compared with a matched cohort of ABO-compatible allografts
por: Dörje, Christina, et al.
Publicado: (2015)

Impact of Fasting Status and Circadian Variation on the Pharmacokinetics of Mycophenolate Mofetil and the Glucuronide Metabolite in Renal Transplant Recipients
por: Drevland, Ole Martin, et al.
Publicado: (2023)

Cardiovascular Risk Following Conversion to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: A Randomized Clinical Trial
por: Bredewold, Obbo W., et al.
Publicado: (2022)

Efficacy and Safety of Belatacept Treatment in Renal Allograft Recipients at High Cardiovascular Risk—A Single Center Experience
por: Neuwirt, Hannes, et al.
Publicado: (2019)

Symmetric Dimethylarginine as Predictor of Graft loss and All-Cause Mortality in Renal Transplant Recipients
por: Pihlstrøm, Hege, et al.
Publicado: (2014)

Importance of hematocrit for a tacrolimus target concentration strategy
por: Størset, Elisabet, et al.
Publicado: (2013)

Time-Limited Therapy with Belatacept in Kidney Transplant Recipients
por: Letellier, Thibault, et al.
Publicado: (2022)

Should patients older than 65 years be offered a second kidney transplant?
por: Heldal, Kristian, et al.
Publicado: (2017)

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients
por: Pihlstrøm, Hege Kampen, et al.
Publicado: (2020)

Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling
por: Størset, Elisabet, et al.
Publicado: (2014)

De Novo Belatacept in a Kidney-After-Heart Transplant Recipient
por: Schenk, Austin D., et al.
Publicado: (2019)

Belatacept-based immunosuppressive regimen in HIV-positive kidney transplant recipients
por: El Sakhawi, Karim, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation in Kidney Transplant Recipients Treated With Belatacept
por: Schwarz, Chloë, et al.
Publicado: (2023)

Individualization of Mycophenolic Acid Therapy through Pharmacogenetic, Pharmacokinetic and Pharmacodynamic Testing
por: Winnicki, Wolfgang, et al.
Publicado: (2022)

The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients
por: AbdElhalim, Mohamed S., et al.
Publicado: (2020)

Belatacept conversion in African American kidney transplant recipients with severe renal dysfunction
por: Snyder, Heather S, et al.
Publicado: (2016)

Optimization of de novo belatacept‐based immunosuppression administered to renal transplant recipients
por: Kirk, Allan D., et al.
Publicado: (2020)

Early calcineurin-inhibitor to belatacept conversion in steroid-free kidney transplant recipients
por: Tawhari, Ibrahim, et al.
Publicado: (2022)

Immunomics of Renal Allograft Acute T Cell-Mediated Rejection Biopsies of Tacrolimus- and Belatacept-Treated Patients
por: van der Zwan, Marieke, et al.
Publicado: (2018)

Impact of SLCO1B3 Polymorphisms on Clinical Outcomes in Lung Allograft Recipients Receiving Mycophenolic Acid
por: Tague, Laneshia K., et al.
Publicado: (2019)

Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
por: Coscia, Lisa, et al.
Publicado: (2023)

A novel direct method to determine adherence to atorvastatin therapy in patients with coronary heart disease
por: Kristiansen, Oscar, et al.
Publicado: (2019)

Pharmacokinetics and Pharmacodynamics of Immediate- and Modified-Release Mycophenolic Acid Preparations in Healthy Beagle Dogs
por: Klotsman, Michael, et al.
Publicado: (2021)

Early Conversion from Tacrolimus to Belatacept in a Highly Sensitized Renal Allograft Recipient with Calcineurin Inhibitor-Induced de novo Post-Transplant Hemolytic Uremic Syndrome
por: Tatapudi, Vasishta S., et al.
Publicado: (2018)

Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation
por: Åsberg, Anders, et al.
Publicado: (2013)

Belatacept: Good, but not good enough?
por: Parameswaran, Sreejith, et al.
Publicado: (2012)

Belatacept: the challenges with transformational drugs
por: Vincenti, Flavio
Publicado: (2017)

Predicting donor, recipient and graft survival in living donor kidney transplantation to inform pretransplant counselling: the donor and recipient linked iPREDICTLIVING tool – a retrospective study
por: Haller, Maria C., et al.
Publicado: (2020)

Donor-Derived Cell-Free DNA for Kidney Allograft Surveillance after Conversion to Belatacept: Prospective Pilot Study
por: Osmanodja, Bilgin, et al.
Publicado: (2023)

Increased risk of ischaemic heart disease after kidney donation
por: Haugen, Anders J, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_06q32420bn4m15mhnrin5heuv3